What Actually Lifts the Low Side

Bipolar depression has treatments with evidence behind them. Several specific medicines can reduce depressive symptoms. Therapy can support recovery alongside medicine, and ECT may be an option when illness is severe, urgent, or has resisted treatment. The best next choice depends on your bipolar type, current symptoms, past response, health, and what you can realistically tolerate.

You should leave a treatment visit knowing what the next step aims to improve and when it will be reviewed. Being told why an antidepressant alone may be a poor fit is only part of that conversation. You also deserve an answer to “What can help me now?” The VA/DoD guideline provides a treatment framework, with different strengths of evidence for different options.1

Key takeaways

• Bipolar depression has treatments with evidence behind them, and the best next step depends on your bipolar type, current symptoms, past response, and what you can tolerate.
• FDA approval, a guideline recommendation, and a study result are three different meanings of “supported,” which is why the exact medicine matters more than its class name.
• A new rash on lamotrigine, new severe restlessness, or a dangerous deterioration is a reason to seek help now, not to wait for a scheduled review.

Zoom

Start with the depression you are living through

Describe both symptoms and their cost. Perhaps getting dressed takes most of your morning. Perhaps you still go to work but cannot follow a conversation. A treatment goal can be less hopelessness, more interest, or enough energy to prepare a meal. Symptom relief and getting daily life back are related, but they are not identical outcomes.

The team also needs the history around the depression. Bipolar I includes mania at some point. Bipolar II includes hypomania and major depression without a history of mania. Similar low mood does not make their evidence bases identical. Your past response can be useful even when the name of the diagnosis is still being reviewed.

Other questions may change the immediate plan. Are you low and slowed down, or low with racing thoughts and unusual drive? Are you sleeping poorly and exhausted, or sleeping less without feeling tired? New medicines, alcohol or cannabis, physical illness, and missed treatment can all complicate the picture. This assessment is meant to improve the fit of care.

A garden analogy offers one small point: two plants with similar-looking low growth may need different conditions. It stops there. Bipolar depression is not a simple deficiency, and you are not a passive plant waiting for someone else to fix you. The literal question is which treatment has evidence for your illness phase and needs.

Three different meanings of “supported”

FDA approval means that a particular product has a U.S. indication for a defined use. A guideline recommendation weighs evidence and clinical judgment. A study may investigate a use outside the FDA label. Those categories overlap, but they are not the same.

That is why the exact medicine matters. A drug called an antipsychotic may have been studied for bipolar depression even when you have never had psychosis. Another drug in the same class may help mania but lack useful evidence for the depressed pole. The class name is not a statement about who you are.

The following groups are prompts for a discussion, not a treatment ladder. Your clinician may have good reasons to consider a different order. The full technical comparison, with formulation, age, bipolar type, and study details, belongs in the conversation with your prescriber.

The quetiapine, lumateperone, lurasidone, cariprazine, and olanzapine-fluoxetine labels define those uses.3 Approval for mania in children does not create approval for childhood bipolar depression.6457

Benefits and burdens belong in the same discussion

Quetiapine has large acute-depression evidence, but sleepiness and metabolic effects can be important. Olanzapine-fluoxetine can also help bipolar I depression, with weight and metabolic burden often central to the choice. A drug that helps mood but makes mornings unworkable needs an honest review.

Lurasidone can be used alone for bipolar I depression or, in adults, with lithium or valproate. It must be taken with food of at least 350 calories for the labeled administration conditions. Ask how that requirement fits poor appetite or an irregular schedule. Restlessness, nausea, and sleepiness are possible concerns.

Cariprazine can cause akathisia, a distressing sense of inner restlessness that may make sitting still hard. Some effects can emerge after a delay because the drug and its active breakdown products remain in the body. Lumateperone can cause sleepiness and dizziness. Small average metabolic changes in a short trial do not mean that monitoring is unnecessary.

Ask about movement effects, blood pressure, weight, glucose, and cholesterol when relevant to the chosen medicine. Also ask about cost, coverage, food, and the plan if side effects interfere with taking it. A refill that cannot be obtained is part of the treatment problem.

Lamotrigine needs a careful explanation

Lamotrigine has an established maintenance role in adults with bipolar I disorder, especially when future depression is a concern. Its U.S. label does not establish efficacy for treating an acute mood episode. That label statement does not mean research has found no acute-depression benefit.

An analysis that combined individual data from five randomized trials found a modest average acute benefit. Guidelines interpret that evidence differently. CANMAT includes an acute role, while VA/DoD finds the evidence insufficient for lamotrigine alone and supports selected add-on use more cautiously.2 The original pooled analysis helps explain why “maintenance only” is too simple.8

Lamotrigine must be introduced carefully, so it is not a rapid rescue for someone in immediate danger. Do not speed it up yourself. Its label calls for stopping at the first sign of rash unless the rash is clearly unrelated to the drug. Seek urgent clinical advice for a rash; blistering, mouth sores, fever, or feeling very ill needs emergency assessment. Serious rash can occur beyond the early weeks.

An interruption also needs drug-specific restart advice. Do not resume the old dose or copy a schedule online. Other medicines and the length of the gap affect that decision. Current prescribing information supplies the safety rules the team must apply.9

Lithium connects several parts of care

Lithium may be an option because of past benefit, the wider bipolar course, or a need for ongoing prevention. Its role in acute depression is different from its stronger role in preventing future episodes. A discussion should make that difference clear instead of promising the same effect at every phase.

It also involves timed levels, kidney and thyroid checks, other monitoring, and a review of interactions. Those practical demands can be manageable with a clear plan. They should not be hidden from you. If lithium is being considered, ask who will arrange the tests and what to do during illness.

Lithium is often discussed in relation to suicide. A large Swedish register study found fewer suicide-related events during lithium-treated periods than during untreated periods in the same people. That was an association, not a randomized test. The original study cannot promise an immediate effect for one person.16 Evidence from different study designs does not give one simple answer, and randomized trials have too few deaths to establish a precise effect. It must not be presented as a guaranteed immediate antisuicide treatment. A review of randomized trials found large uncertainty.10

Where antidepressants may fit

Some guidelines consider selected antidepressants in certain conditions, with attention to bipolar type, mixed symptoms, previous activation, and whether other treatment is present. Bipolar I depression is not a setting for a routine antidepressant-alone plan. Selected nonmixed bipolar II depression raises a different discussion.

An antidepressant does not cause a switch in every person. Taking another medicine alongside it does not remove all risk. If it is used, ask what benefit is expected, what early change to report, and how continuation will be reviewed. The earlier antidepressant essay explains that issue in greater depth; it should not replace a discussion of what treats the current low.

If the first plan has not helped enough

Tell the team what has changed and what has not. “I am sleeping more, but I still cannot eat or work” is more useful than a single label of better or worse. Bring side effects and missed doses into the same conversation. A limited benefit does not prove that you have failed treatment.

The review may revisit diagnosis, whether the trial was adequate, tolerability, sleep problems, medical contributors, substances, and access. It may also ask whether treatment is reducing symptoms while leaving function behind. The time needed to assess an option depends on the drug and your condition.

You should not be told to endure dangerous deterioration until a fixed week count has passed. A clinician can reconsider the level of care before the usual review date. Ask for a plan that explains both routine follow-up and the route for worsening symptoms.

When specialist treatments belong in the conversation

ECT uses a controlled procedure under anesthesia. It is an established option to discuss for severe, urgent, or treatment-resistant bipolar depression. In a randomized inpatient study, it improved response more than a medication algorithm, while remission did not clearly differ. Memory effects, anesthesia, consent, and follow-up care matter. The original trial concerns resistant illness, not every depressive episode.11

rTMS uses magnetic stimulation and is a different treatment. A 2026 review found a modest pooled symptom benefit in small bipolar trials, with real uncertainty. Ketamine and esketamine also require a separate discussion; promising short-term findings do not establish long-term bipolar benefit. An MDD or treatment-resistant-depression approval must not be presented as a bipolar approval. The rTMS review and esketamine label preserve these distinctions.1213

Bright-light treatment has a selected, supervised adjunctive role in specialist guidance.14 Timing, exposure, and activation monitoring matter; this is not a home light-box recipe. Therapy and steady daily supports also have roles, but neither should be sold as enough for a severe acute episode.

Ask what improvement would look like

Before the visit ends, choose a sign of progress that matters to you. It might be getting out of bed with less effort or being able to follow a short call. Ask how that goal fits the symptom change the clinician will track. You can feel somewhat better and still need more help with daily life.

You can also name a burden you could not manage for long. “I need to drive early for work” or “I cannot afford a second monthly copay” gives the team useful facts. Ask what to do if that burden appears. You should not have to choose alone between taking a drug that feels unworkable and stopping without advice.

If you struggle to speak during a visit, hand over a short note. Include one thing that has helped, one thing that remains hard, and your main question. You may invite a trusted person to help you remember the plan, if you want. The decision should still make room for your own goals and voice.

Make the next visit concrete

Hypothetical conversation: “My low mood has not lifted enough to cook or answer work messages. I want to understand which options have evidence for my bipolar type. Sedation is the side effect I most need us to plan around. What will we review next, and whom do I contact if I get worse?”

Seek help sooner: new severe restlessness, rapidly changing sleep need, rising energy with hopelessness, or marked loss of function deserves prompt assessment. Inability to eat or drink, psychosis with unsafe behavior, or suicidal thoughts with immediate danger requires emergency help. Call 911 for immediate medical or physical danger. Call or text 988 (the Suicide & Crisis Lifeline) when you need help deciding how to stay safe.15 Do not wait for treatment to have more time.

This week, choose one symptom and one everyday task you want treatment to improve, and bring both to your next bipolar-care visit.

Frequently asked questions

Are the options different from regular depression treatment?

Yes, the history of mania or hypomania can change the evidence and the risks to consider. Several medicines have specific bipolar-depression evidence, while an MDD approval may not apply. The choice also depends on bipolar type, mixed symptoms, prior benefit, and urgency. Ask the clinician to explain the match between the option and your actual history.

Why prescribe a medicine called an antipsychotic?

Some medicines in that class have been tested for bipolar depression and help people who have no psychosis. The name reflects a drug class, not a judgment about you. The specific drug matters because the whole class does not work equally for every phase. Ask what this medicine is meant to improve and what burdens need monitoring.

Why does lamotrigine take time?

It needs careful introduction because of rash risk, and that limits its use as a rapid rescue. Its maintenance role and possible acute benefit are different questions. Do not speed up the schedule or restart an old dose after an interruption without advice. A new rash needs urgent clinical attention under its drug-specific instructions.

Can antidepressants ever be used?

Sometimes, in selected circumstances. Bipolar type, mixed symptoms, previous activation, and whether the drug is added to another treatment all matter. Guidelines differ in how they weigh benefit and risk. A plan should include early warning signs and a review of ongoing use. Neither a universal ban nor a guarantee of protection fits the evidence.

What if the first treatment does not work?

Return with specific information about symptoms, daily function, side effects, and what you actually took. The team can review the diagnosis, trial, medical or sleep contributors, and other options. Limited benefit is a reason to reassess, not a personal failure. Ask how soon the next decision will be made and what would bring that review forward.

When is waiting unsafe?

Do not wait for a scheduled review when you cannot maintain food or fluids, are rapidly deteriorating, have severe agitation or new psychosis, or face immediate self-harm danger. The needed route depends on severity, but urgent assessment should not require a completed symptom checklist. Call 911 for immediate medical or physical danger.

This article is for education, not personal medical advice. Do not start, stop, restart, or change a medication without the clinician who manages it. Every PubMed citation, crisis number, and internal link in this article was verified against its primary source on September 8, 2026. Guidelines, drug labels, and public-health data change; confirm current status before acting on anything here.

Related reading on NP FADY

• “A Sail Without a Keel”: When an Antidepressant Alone Can Make Things Worse
• The Bridge You Don’t Notice
• Fast and Heavy at the Same Time
• “You Only Photograph the Low Tide”: Why It Gets Called Depression First
• “The Shout and the Hum”: Bipolar I vs. Bipolar II
• Modern ECT for Depression: Procedure, Benefits, Memory, and Safety

References

1. VA/DoD. Clinical Practice Guideline for Management of Bipolar Disorder. May 2023. Full guideline.

2. Yatham LN, et al. CANMAT/ISBD guidelines. Bipolar Disorders. 2018;20:97–170. doi:10.1111/bdi.12609. Full guideline.

3. DailyMed. Quetiapine immediate-release tablets prescribing information. January 2025. Label.

4. Sunovion. LATUDA prescribing information. January 2025. Label.

5. AbbVie. VRAYLAR prescribing information. December 2025. Label.

6. FDA. CAPLYTA prescribing information. 2026. Label.

7. Lilly. SYMBYAX prescribing information. Current version accessed 2026-09-08. Label.

8. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. British Journal of Psychiatry. 2009;194:4–9. doi:10.1192/bjp.bp.107.048504. Original analysis.

9. GSK. LAMICTAL prescribing information. October 2025. Full label.

10. Nabi Z, Stansfeld J, Plöderl M, Wood L, Moncrieff J. Effects of lithium on suicide and suicidal behaviour: a systematic review and meta-analysis of randomised trials. Epidemiology and Psychiatric Sciences. 2022;31:e65. doi:10.1017/S204579602200049X. Original abstract.

11. Schoeyen HK, et al. Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment. American Journal of Psychiatry. 2015;172:41–51. doi:10.1176/appi.ajp.2014.13111517. Original trial.

12. Zhou C, Fabiano N, Wong S, et al. Transcranial Magnetic Stimulation for Bipolar Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Canadian Journal of Psychiatry. Published June 4, 2026. doi:10.1177/07067437261457224. Original review.

13. Janssen. SPRAVATO prescribing information. January 2025. FDA label.

14. Geoffroy PA, et al. Light therapy for bipolar disorders: clinical recommendations from the ISBD Chronobiology and Chronotherapy Task Force. 2025. Original publication.

15. Suicide & Crisis Lifeline. Get help. Accessed 2026-09-08. Official support route.

16. Song J, Sjölander A, Joas E, et al. Suicidal Behavior During Lithium and Valproate Treatment: A Within-Individual 8-Year Prospective Study of 50,000 Patients With Bipolar Disorder. American Journal of Psychiatry. 2017;174(8):795–802. doi:10.1176/appi.ajp.2017.16050542. Original report.

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.